Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Phase 2 Terminated 3 enrolled Johns Hopkins University BioMarin Pharmaceutical · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to assess the safety and efficacy of twice-daily oral dosing of 6R-BH4 to improve endothelial function, reduce systolic blood pressure and reduce arterial stiffness.

Timeline

Start: 2008-12
Primary completion: 2009-05
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	sapropterin	Unknown	5 mg/kg	Oral

Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Summary

Timeline

Drugs

Indications